Vir Biotechnology Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Vir Biotechnology, Inc. (Nasdaq: VIR) successfully closed its public offering, selling 8,214,285 shares at $42.00 each, generating gross proceeds of approximately $345.0 million.

Rhea-AI Summary

Vir Biotechnology, Inc. (Nasdaq: VIR) successfully closed its public offering, selling 8,214,285 shares at $42.00 each, generating gross proceeds of approximately $345.0 million. The offering included an option for underwriters to purchase an additional 1,071,428 shares. Registration for these securities became effective on July 7, 2020. Joint book-running managers included Goldman Sachs, BofA Securities, Cowen, and Barclays. The funds raised are intended to support Vir's clinical-stage pipeline focused on serious infectious diseases, including hepatitis B and SARS-CoV-2.

Positive

• Gross proceeds of approximately $345.0 million from the public offering will support clinical-stage product candidates.
• Successful closure of the offering indicates strong investor interest and confidence in Vir Biotechnology's pipeline.

Negative

• Dilution of existing shares may occur due to the additional shares offered.

Argus Session date unavailable

+3.10% session move Open Argus

Details

News Market Reaction – VIR

The recorded move for VIR in the trading session of this news was +3.10%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO, July 10, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced the closing of its previously announced underwritten public offering of 8,214,285 shares of its common stock at a public offering price of $42.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 1,071,428 additional shares of common stock. The aggregate gross proceeds to Vir from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses, were approximately $345.0 million.

Goldman Sachs & Co. LLC, BofA Securities, Cowen and Barclays acted as joint book-running managers for the offering. Needham & Company acted as lead-manager for the offering.

Registration statements relating to these securities have been filed with the Securities and Exchange Commission (SEC) and became effective on July 7, 2020. The offering was made only by means of a prospectus. Copies of the final prospectus related to the offering may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com; BofA Securities, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email at dg.prospectus_requests@bofa.com; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, by email at PostSaleManualRequests@broadridge.com, or by telephone at (833) 297-2926; or Barclays Capital Inc., c/o Broadridge Financial Solutions, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (888) 603-5847, or by email at Barclaysprospectus@broadridge.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Vir Biotechnology

Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting hepatitis B virus, influenza A, SARS-CoV-2, human immunodeficiency virus and tuberculosis.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was the size of Vir Biotechnology's public offering?

Vir Biotechnology's public offering consisted of 8,214,285 shares at a price of $42.00 per share, totaling approximately $345.0 million in gross proceeds.

What does the public offering mean for Vir Biotechnology shareholders?

The public offering may lead to dilution of existing shares, potentially affecting current shareholders' equity.

When did Vir Biotechnology's public offering become effective?

The registration statement for Vir Biotechnology's public offering became effective on July 7, 2020.

How will Vir Biotechnology use the funds raised from the offering?

The funds raised will support the clinical development of Vir's product candidates targeting serious infectious diseases.